Search for: "Taylor et al v. General Electric Company et al" Results 1 - 10 of 10
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Oct 2007, 7:03 am
The case was General Electric v. [read post]
17 Apr 2015, 8:58 am by WIMS
  The Climate Post: Court Hears Arguments Surrounding EPA Power Plant Rule State of West Virginia, et al. v. [read post]
18 May 2009, 5:24 am
: Omnicare, Inc v OHIM, Astellas Pharma GmbH (Class 46) CFI delivers judgment in case concerning ability of designer who assigns business and related IP to another company, to object when the company tries to register his name as a CTM: Elio Fiorucci v OHIM (IPKat) CFI: Good faith irrelevant when selling non-misleading sausages: Alberto Severi, in his own name and representing Cavazzuti e figli SpA, now known as Grandi Salumifici Italiani SpA v Regione… [read post]
14 Jan 2010, 5:23 am by Sean Wajert
Du Pont de Nemours & Co., et al., 82 F.3d 894 (9th Cir. 1996) (applying Hawaii law); Jacobs v. [read post]
2 May 2008, 7:00 am
: Lupin v Abbott Labs: (FDA Law Blog), Plavix (Clopidogrel) – US: Apotex sues FDA to recover 180-day exclusivity on generic Plavix: (Orange Book Blog), Plavix (Clopidogrel) – US: Former Bristol-Myers Squibb executive charged over lying about Plavix deal struck with rival Apotex: (Managing Intellectual Property), Risperdal (Resperidone) – US: Apotex files motion to intervene in relisting of Risperdal patent case; Teva quickly files… [read post]
14 Mar 2016, 2:56 am by Kevin LaCroix
  “Direct means Direct” generally limits coverage to losses of assets that the insured held in an account for a customer or owned by the insured. [2]   In Cumberland & Erly, LLC v. [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation… [read post]